HIV strength battles looming Biktarvy price cuts
- HIV sales grew 18% year over year in Q3 2026, reaching $6.2 billion.
- Management expects a $1.5 billion revenue hit in 2028 from Medicare price cuts to Biktarvy.
- Trodelvy sales rose 42% year over year in Q3 2026, hitting a $2 billion annual run rate.
- Cell Therapy sales fell 18% year over year in Q3 2026 to $355 million as competition intensified.
The HIV engine accelerates into a major test
Gilead's core HIV business is accelerating. In Q3 2026, base business revenue grew 16% year over year. The HIV franchise surged 18%, driven by strong demand for Biktarvy and the prevention drug Yeztugo.
But a major structural headwind is now quantified. Medicare set the 2028 negotiated price for Biktarvy at a 38% discount. Management expects this to create a $1.5 billion net revenue hit in 2028 across all government channels.
The company must offset that hit with growth in oncology and inflammation. The results are split. Trodelvy grew 42% year over year in Q3 2026, but the Cell Therapy franchise dropped 18% and faces new clinical holds in its pipeline.
The stock story is a race against time. Gilead has a massive cash engine in HIV and a pending FDA decision for its anito-cel blood cancer therapy. But it must execute flawlessly to outrun the coming 2028 price cuts and fix its struggling cell therapy business.
Patented drugs, concentrated cash flow
Gilead discovers, develops, and sells prescription medicines for serious diseases. Most revenue comes from patented drugs sold through wholesalers. That means pricing, patent life, insurance access, and doctor use matter heavily.
HIV is the main profit driver. Biktarvy leads in treatment, while Descovy and Yeztugo drive prevention. This franchise funds research, dividends, share repurchases, and acquisitions.
The risk is concentration. If HIV pricing falls, the whole company feels it. Oncology and inflammation are supposed to reduce that dependence, but the results remain mixed.
Gilead relies heavily on acquisitions to build its non-HIV pipeline. Buying outside science brings new drugs faster than internal research, but it adds integration risk and immense upfront costs.
The drugs that matter most
Biktarvy
Biktarvy is Gilead's flagship HIV treatment. Medicare price negotiation will force a 38% discount starting in 2028.
Yeztugo
Yeztugo is a long-acting HIV prevention shot that is fueling higher franchise growth and hitting a $1 billion annual run rate.
Descovy and other HIV medicines
Descovy for prevention continues to grow, while Genvoya, Odefsey, and Symtuza support the broader HIV base.
Trodelvy
Trodelvy is the stronger part of Gilead's oncology portfolio right now. Q3 2026 sales were $506 million, up 42% year over year.
Yescarta and Tecartus
These Cell Therapy products were meant to diversify Gilead. Q3 2026 sales were $355 million, down 18% year over year because of competition.
Livdelzi and liver disease drugs
Liver Disease sales were $927 million in Q3 2026, up 13% year over year, helped by the new primary biliary cholangitis drug Livdelzi.
Veklury
Veklury is Gilead's COVID-19 antiviral. Full year 2026 guidance is approximately $300 million due to lower hospitalizations.
Q3 sales rely heavily on HIV
This mix uses Gilead's product group sales for the three months ended September 30, 2026. The listed product groups total just under reported product sales because of rounding.
What could go wrong
Biktarvy price cut in 2028
High impact · High oddsMedicare set a 38% discount for Biktarvy effective 2028. Management estimates a $1.5 billion net revenue headwind across all government channels.
Cell Therapy keeps losing share
Medium impact · High oddsCell Therapy sales fell 18% year over year in Q3 2026. A partial clinical hold on the KITE-753 pipeline asset adds further pressure.
M&A becomes too much to digest
Medium impact · Medium oddsGilead is using large deals to build oncology and inflammation. This adds massive integration costs and heightens the risk of distracting the team from the core HIV business.
Oncology pipeline disappoints again
Medium impact · Medium oddsTrodelvy is growing, but it took a $1.75 billion impairment charge in Q2 2026 for its lung cancer program. More failures would hurt the case that oncology can become a second growth pillar.
Drug channel and legal pressure
Medium impact · Medium oddsGilead disclosed risks tied to counterfeit versions of its medicines and legal fights around the 340B drug pricing program. Counterfeits can hurt patients and trust.
In one breath
What does Gilead Sciences make?
Gilead makes prescription medicines for HIV, liver disease, cancer, inflammation, and viral infections. Its most important business is HIV, led by Biktarvy for treatment and Yeztugo and Descovy for prevention.
Why is Yeztugo important for Gilead?
Yeztugo is a twice-yearly HIV prevention shot, which makes it easier for some people than taking pills often. It is helping the prevention business reach a $1 billion annual run rate.
What is the biggest risk for Gilead stock?
The biggest risk is that Gilead depends heavily on HIV while Biktarvy faces a massive Medicare price cut in 2028. Management expects a $1.5 billion revenue headwind from this change.
Is Gilead growing outside HIV?
Yes, but the picture is mixed. Trodelvy grew 42% year over year in Q3 2026, while Cell Therapy sales fell 18% year over year because of intense competition.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- November 1, 2026
- Score data
- November 15, 2026
- Reviewed by
- Shivam Bharuka
Comparable Drug Manufacturers - General companies
Companies near Gilead Sciences, Inc. in Finn's Drug Manufacturers - General industry ranking.

